Continue to Site

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

Home » FDA accepts biologics license application for Genentech’s drug-eluting eye implant

FDA accepts biologics license application for Genentech’s drug-eluting eye implant

By

Genentech PDS implant
Genentech’s PDS implant. [Image from Genentech]
Genentech announced that the FDA accepted its Biologics License Application (BLA) for its Port Delivery System (PDS) with ranibizumab.

The PDS is a permanent, refillable eye implant standing at the approximate size of a grain of rice. It offers continuous delivery of a customized formulation of ranibizumab over a period of months to reduce the treatment burden associated with frequent eye injections.

Get the full story at our sister site, Drug Delivery Business News.

More recent news

About Sean Whooley

Sean Whooley is an associate editor who mainly produces work for MassDevice, Medical Design & Outsourcing and Drug Delivery Business News. He received a bachelor's degree in multiplatform journalism from the University of Maryland, College Park. You can connect with him on LinkedIn or email him at swhooley@wtwhmedia.com.

Copyright © 2024 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy